Science Explorer Back to mapMap

Most cited papers from Gastro One (United States)

What are the most cited papers from Gastro One (United States)?

The most cited paper from Gastro One (United States) is "Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection" (Nezam H. Afdhal et al., 2014), with 1,312 citations. Next come "ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV" (697) and "All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study" (694).

Showing 50 of 54 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection Nezam H. Afdhal et al. · New England Journal of Medicine 12 Apr 2014 1,312
2 ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV Péter Ferenci et al. · New England Journal of Medicine Open access 4 May 2014 697
3 All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study David R. Nelson et al. · Hepatology Open access 23 Jan 2015 694
4 Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection Marc Bourlière et al. · New England Journal of Medicine 31 May 2017 571
5 Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials Stephen A. Harrison et al. · Journal of Hepatology 640 authors 5 Mar 2020 494
6 Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH Rohit Seth Loomba et al. · Hepatology 10 Nov 2020 290
7 Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials Quentin Mark Anstee et al. · Hepatology 4 Jul 2019 276
8 Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis Stephen A. Harrison, Guy W. Neff, Cynthia D. Guy et al. · Gastroenterology Open access 8 Aug 2020 271
9 A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis Stephen A. Harrison, Zachary D Goodman, Abdul Jabbar et al. · Journal of Hepatology 27 Dec 2019 260
10 Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks Jordan J. Feld, Christophe Moreno, Roger N. Trinh et al. · Journal of Hepatology Open access 25 Oct 2015 162
11 Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension Guadalupe García–Tsao et al. · Journal of Hepatology Open access 21 Dec 2019 160
12 Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial Stephen A Harrison et al. · ˜The œLancet. Gastroenterology & hepatology 21 Mar 2022 137
13 Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations Zobair M. Younossi, Mazen Noureddin, David Eliot Bernstein et al. · The American Journal of Gastroenterology Open access 6 Dec 2020 106
14 A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients With Nonalcoholic Steatohepatitis Mohammad Shadab Siddiqui, Michael O. Idowu, Dhruvanshu Parmar et al. · Clinical Gastroenterology and Hepatology 2 Nov 2020 92
15 A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis Mary Eugenia Rinella, Hsiao Dee Lieu, Kris V. Kowdley et al. · Hepatology Open access 21 Sep 2023 90
16 Ledipasvir‐sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens David L. Wyles, Paul J. Pockros, Giuseppe Morelli et al. · Hepatology 2 Apr 2015 89
17 Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial Eric Lawitz et al. · Gastroenterology Open access 31 Jul 2016 53
18 A Phase 2, Randomized, Placebo-Controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andecaliximab, in Patients With Moderately to Severely Active Crohn’s Disease Stefan Schreiber, Corey Allan Siegel, Keith Friedenberg et al. · Journal of Crohn s and Colitis Open access 28 May 2018 52
19 Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease William J. Sandborn, Bal Raj Bhandari, Charles W. Randall et al. · Journal of Crohn s and Colitis Open access 13 May 2018 50
20 Clinical triage decision vs risk scores in predicting the need for endotherapy in upper gastrointestinal bleeding Farees T. Farooq, Michael Ho-Yan Lee, Ananya Das et al. · The American Journal of Emergency Medicine 25 Dec 2010 50
21 Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders Donald M. Jensen et al. · Journal of Hepatology 19 Feb 2015 46
22 Randomized Study of Asunaprevir plus Pegylated Interferon-α and Ribavirin for Previously Untreated Genotype 1 Chronic Hepatitis C Jean-Pierre Bronowicki et al. · Antiviral Therapy Open access 26 Jun 2013 46
23 The emergence of NS5B resistance associated substitution S282T after sofosbuvir‐based treatment Edward John Gane, Sophie Métivier, Ronald Nahass et al. · Hepatology Communications Open access 22 Jun 2017 42
24 Decreased Antibody Responses to Ad26.COV2.S Relative to SARS-CoV-2 mRNA Vaccines in Patients With Inflammatory Bowel Disease Valeriya Pozdnyakova et al. · Gastroenterology Open access 12 Aug 2021 34
25 Quality of Care Program Reduces Unplanned Health Care Utilization in Patients With Inflammatory Bowel Disease GIL Y. MELMED et al. · The American Journal of Gastroenterology Open access 19 Nov 2021 32
26 Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials Vincent Wai‐Sun Wong, Won Young Tak, George Boon‐Bee Goh et al. · Clinical Gastroenterology and Hepatology Open access 22 Jan 2022 29
27 Low Relapse Rate Leads to High Concordance of Sustained Virologic Response (SVR) at 12 Weeks With SVR at 24 Weeks After Treatment With ABT-450/Ritonavir, Ombitasvir, and Dasabuvir Plus Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection in the AVIATOR Study Fred F Poordad, Kosh Agarwal, Ziad H Younes et al. · Clinical Infectious Diseases Open access 2 Nov 2014 27
28 Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease Stephen A. Harrison, Seth J. Baum, Nadege Gunn et al. · The American Journal of Gastroenterology Open access 12 Aug 2021 26
29 Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C Jean–Pierre Bronowicki, Vlad Ratziu, Adrian Carlos Gadano et al. · Journal of Hepatology 16 Jul 2014 25
30 Development and Pilot Testing of the Inflammatory Bowel Disease Nutrition Care Pathway Caroline Hwang, Kelly Issokson, Catherine Giguere‐Rich et al. · Clinical Gastroenterology and Hepatology 26 Jun 2020 23
31 Phase 2, open-label, rollover study of cenicriviroc for liver fibrosis associated with metabolic dysfunction–associated steatohepatitis Sven Francque, Alexander D. Hodge, Jérôme Boursier et al. · Hepatology Communications Open access 29 Jan 2024 15
32 Postvaccination Symptoms After a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease: Results From CORALE-IBD Dalin Li et al. · Inflammatory Bowel Diseases Open access 23 Aug 2022 14
33 1420 ASUNAPREVIR WITH PEGINTERFERON-ALFA AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE-1 OR -4 CHRONIC HEPATITIS C: SVR24 RESULTS FROM A RANDOMIZED PHASE 2B STUDY (AI447016) J.‐P. Bronowicki, Vlad Ratziu, Adrian Carlos Gadano et al. · Journal of Hepatology Open access Apr 2013 11
34 Health Economic Impact of a Multicenter Quality-of-Care Initiative for Reducing Unplanned Healthcare Utilization Among Patients With Inflammatory Bowel Disease Christopher V. Almario et al. · The American Journal of Gastroenterology Open access 3 Nov 2021 10
35 Not Achieving Sustained Viral Eradication of Hepatitis C Virus After Treatment Leads to Worsening Patient-reported Outcomes Zobair M. Younossi, Maria A. Stepanova, Ira M. Jacobson et al. · Clinical Infectious Diseases Open access Apr 2019 10
36 Safety and efficacy of combination therapies including cilofexor/ firsocostat in patients with bridging fibrosis and cirrhosis due to NASH: Results of the phase 2b ATLAS trial Rohit Seth Loomba et al. · Journal of Hepatology Aug 2020 9
37 The Effect of EndocuffTM—-Assisted Colonoscopy on Adenoma Detection Rate: A Randomized Trial in Community Ambulatory Surgical Centers Edward L. Cattau, Rolando J. Leal, Eric J. Ormseth et al. · The American Journal of Gastroenterology Oct 2015 9
38 Hypervascular lesions of the pancreas: Think before you act Susan M. Wcislak, Zachary E. Stiles, Jeremiah Lee Deneve et al. · The American Journal of Surgery 27 Nov 2018 9
39 Ombitasvir/paritaprevir/ritonavir and dasabuvir with or without sofosbuvir for patients with hepatitis C virus genotype 1 infection who failed a prior course of direct‐acting antiviral therapy Fred F Poordad, MICHAEL R. BENNETT, Thomas E. Sepe et al. · Journal of Medical Virology 6 Mar 2019 7
40 Reinduction with Certolizumab Pegol in Patients with Crohnʼs Disease Experiencing Disease Exacerbation Scott David Lee, David T. Rubin, William J. Sandborn et al. · Inflammatory Bowel Diseases Open access 9 Jul 2016 7
41 A multi-analyte cfDNA-based blood test for early detection of hepatocellular carcinoma David J. Taggart et al. · Journal of Hepatology Open access 6 May 2026 5
42 Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin Jordan J. Feld, David E. Bernstein, Ziad H Younes et al. · Liver International Open access 29 Jan 2018 5
43 Postvaccination Symptoms After a Fourth Dose of mRNA SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease Yoo Jin Lee et al. · Inflammatory Bowel Diseases Open access 29 Sep 2023 2
44 Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studies Stuart C. Gordon, Alejandra Villamil, Ira M. Jacobson et al. · Hepatology Communications Open access 13 Apr 2026 1
45 Integrated IBD Care in the Community: Evaluating Sustainable Models and Building a Framework for the Future Erica R. Cohen, Timothy Ritter, William H. Holderman et al. · Gastroenterology 20 Nov 2025 1
46 Efficacy and Safety of Seladelpar in Patients With Primary Biliary Cholangitis and Compensated Liver Cirrhosis in the Open-Label, Long-Term ASSURE Safety Study: Interim Results Stuart R. Gordon, Ira M. Jacobson, Ziad H Younes et al. · Zeitschrift für Gastroenterologie Conference paper 2025 1
47 The MRI and AST (MAST) score is correlated with noninvasive and histologic markers of fibrosis in patients with advanced fibrosis due to NASH Mazen Noureddin et al. · Journal of Hepatology Jul 2022 1
48 Positive topline results from a 24-week, randomized, double-blind, placebo-controlled, multicenter, phase 2 study of the FGF19 analogue aldafermin (NGM282) in patients with non-alcoholic steatohepatitis Stephen A. Harrison, Guy W. Neff, Cynthia D. Guy et al. · Journal of Hepatology Aug 2020 1
49 IDDF2019-ABS-0131 Algorithms using noninvasive tests can accurately identify patients with advanced fibrosis due to NASH: data from the STELLAR clinical trials Vincent Wai‐Sun Wong et al. Conference paperOpen access Jun 2019 1
50 Algorithms using noninvasive tests can accurately identify patients with advanced fibrosis due to NASH: data from the STELLAR clinical trials Pietro Lampertico et al. · Digestive and Liver Disease Feb 2019 1

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.